Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03146416 · ClinicalTrials.gov registry record · Phase 1
Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT03146416 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 96 participants.
The verdict
NCT03146416, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
The primary objective of the study is to compare the safety and tolerability of subcutaneous (SC) and intravenous (IV) doses of evinacumab in healthy Japanese and Caucasian subjects.
Interventions
- DRUG Placebo
- DRUG Evinacumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2017-05-16 |
| Est. Completion | 2018-06-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03146416
The ClinicalTrials.gov registry entry for NCT03146416 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03146416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03146416 about?
NCT03146416 is a clinical study titled "Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers". The primary objective of the study is to compare the safety and tolerability of subcutaneous (SC) and intravenous (IV) doses of evinacumab in healthy Japanese and Caucasian subjects.
What is the current status of trial NCT03146416?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2017-05-16. Estimated completion is 2018-06-14.
What interventions are being tested in trial NCT03146416?
The interventions under investigation include: Placebo (DRUG), Evinacumab (DRUG).
Who is sponsoring clinical trial NCT03146416?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.